Plasma levels of tumor necrosis factor-alpha in patients with visceral leishmaniasis (Kala-Azar). Association with activity of the disease and clinical remisson following antimonial therapy
Autor: | Iara Marques Medeiros, Adauto Castelo Filho, Miguel Angel Sicolo, Reinaldo Salomão |
---|---|
Přispěvatelé: | Universidade Federal de São Paulo (UNIFESP), Universidade Federal do Rio Grande do Norte Division of Infectious Diseases |
Jazyk: | angličtina |
Rok vydání: | 1996 |
Předmět: |
medicine.medical_specialty
Antiprotozoal Agents Disease Gastroenterology Immune system Meglumine Internal medicine medicine Organometallic Compounds Humans Cytotoxicity Meglumine Antimoniate medicine.diagnostic_test business.industry Tumor Necrosis Factor-alpha Remission Induction General Medicine Plasma levels medicine.disease Infectious Diseases Visceral leishmaniasis Immunoassay Immunology Antimonial Leishmaniasis Visceral Cytokines Tumor necrosis factor alpha business Visceral Leishmaniasis (Kala-Azar) TNF-alpha |
Zdroj: | Repositório Institucional da UNIFESP Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP Revista do Instituto de Medicina Tropical de São Paulo, Volume: 38, Issue: 2, Pages: 113-118, Published: APR 1996 |
Popis: | Avaliação de TNF-alfa em pacientes com calazar tem despertado grande interesse devido ao seu papel no sistema imunológico e à sua atividade caquetizante. O objetivo deste estudo foi examinar a associação entre os níveis plasmáticos de TNF-alfa, medidos através de sua imunorreatividade (ELISA) e bioatividade (ensaio citotóxico sobre as células L-929), e as manifestações clínicas da leishmaniose visceral. Amostras de 19 pacientes foram obtidas para determinação do TNF-alfa antes, durante e após a terapia antimonial, utilizando o ensaio de citotoxicidade (todos os pacientes) e o ELISA (14 pacientes). Resultados discrepantes entre os ensaios de citotoxicidade e o ELISA foram observados. Níveis circulantes de TNF-alfa, medidos pelo ELISA, foram mais altos nos pacientes que nos controles e declinaram significantemente com a melhora clínica e laboratorial. Níveis plasmáticos antes do tratamento (média = 124,7 pg/ml; DP = 93,3) foram mais elevados que ao final da terapêutica (13,9 pg/ml; DP = 25,1; p = 0,001). Por outro lado, níveis plasmáticos de TNF-alfa, avaliados pela citotoxicidade, não seguiram um curso previsível durante a evolução. Esta discrepância pode ser devida à presença de fatores no plasma que podem influenciar a liberação e atividade do TNF-alfa. Ainda, a lise observada pode não ser totalmente atribuída ao TNF-alfa. Evaluation of TNF-alpha in patients with Kala-azar has drawn increasing interest due to its regulatory role on the immune system, in addition to its cachetizing activity. The objective of this study was to examine the association between plasma levels of TNF-alpha, measured by immunore-activity (ELISA) and bioactivity (cytotoxicity assay with L-929 cells), and clinical manifestations of visceral leishmaniasis. Plasma samples from 19 patients with Kala-azar were obtained before, during and at the end of antimonial therapy. TNF-alpha determinations was done by using the cytotoxicity assay (all patients) and the enzyme-linked immunoassay (ELISA - 14 patients). A discrepancy between results obtained by ELISA and cytotoxicity assay was observed. Levels of circulating TNF-alpha, assessed by ELISA, were higher in patients than in healthy controls, and declined significantly with improvement in clinical and laboratory parameters. Plasma levels before treatment were 124.7 ± 93.3 pg/ml (mean ± SD) and were higher than at the end of therapy 13.9 ± 25.1 pg/ml (mean ± SD) (p = 0.001). In contrast, plasma levels of TNF-alpha evaluated by cytotoxicity assay did not follow a predicted course during follow-up. Lysis, in this case, might be not totally attributed to TNF-alpha. The discrepancy might be attributed to the presence of factor(s) known to influence the release and activity of TNF-alpha. Escola Paulista de Medicina Division of Infectious Diseases Universidade Federal do Rio Grande do Norte Division of Infectious Diseases UNIFESP, EPM, Division of Infectious Diseases SciELO |
Databáze: | OpenAIRE |
Externí odkaz: |